Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: The REPLACE-MS study
Age over 50, Caucasian race, time on therapy 3 or more years were risk factors for HGG.
Authors
- Sophia Woodson
- Michelle Maynard
- Collin Jakubecz (ORCID: https://orcid.org/0000-0002-3863-045X)
- Aram Zabeti (ORCID: https://orcid.org/0000-0002-0424-7460)
- Sara Esmaeili (ORCID: https://orcid.org/0000-0003-0668-5541)
- Ray Hernandez
- Hesham Abboud
- Alessandro Serra
- Ahmed Z Obeidat
- Kiranpal Singh Sangha
Institutions
- Froedtert Hospital (US)
- Medical College of Wisconsin (US)
- University Hospitals of Cleveland (US)
- Cincinnati Health Department (US)
- University Hospitals Cleveland Medical Center (US)
- University School (US)
- Case Western Reserve University (US)
- University of Cincinnati (US)
- The University of Texas Southwestern Medical Center (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1177/13524585251412125
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00